Trial Profile
A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients With C3 Glomerulopathy (C3G), With an Open-label Extension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Danicopan (Primary)
- Indications Glomerulonephritis; Membranoproliferative glomerulonephritis
- Focus Proof of concept; Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease
- 07 May 2021 Status changed from active, no longer recruiting to completed.
- 02 Dec 2019 Planned primary completion date changed from 1 Oct 2019 to 31 Dec 2019.
- 19 Aug 2019 Planned End Date changed from 1 Oct 2019 to 1 May 2020.